<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>329</serviceExecutionTime><Drug id="107078"><DrugName>etanercept biosimilar, Pfizer</DrugName><DrugNamesKey><Name id="43107998">Lifmior</Name><Name id="42756822">etanercept</Name></DrugNamesKey><DrugSynonyms><Name><Value>etanercept</Value><Types><Type>USAN</Type><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>Lifmior</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>etanercept biosimilar, Pfizer</Value></Name></DrugSynonyms><CompanyOriginator id="18767">Pfizer Inc</CompanyOriginator><CompaniesPrimary><Company id="18767">Pfizer Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="1781" type="ciIndication"><TargetEntity id="10037162" type="MEDDRA"></TargetEntity><TargetEntity id="D015535" type="MeSH"></TargetEntity><TargetEntity id="-689721545" type="omicsDisease"></TargetEntity><TargetEntity id="724" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"></TargetEntity><TargetEntity id="10037153" type="MEDDRA"></TargetEntity><TargetEntity id="D011565" type="MeSH"></TargetEntity><TargetEntity id="-1735788310" type="omicsDisease"></TargetEntity><TargetEntity id="490" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2921" type="ciIndication"><TargetEntity id="D025241" type="MeSH"></TargetEntity><TargetEntity id="-172791506" type="omicsDisease"></TargetEntity><TargetEntity id="753" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="398" type="ciIndication"><TargetEntity id="M45" type="ICD10"></TargetEntity><TargetEntity id="720.0" type="ICD9"></TargetEntity><TargetEntity id="10002556" type="MEDDRA"></TargetEntity><TargetEntity id="D013167" type="MeSH"></TargetEntity><TargetEntity id="-605402220" type="omicsDisease"></TargetEntity><TargetEntity id="752" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="380" type="Action"><TargetEntity id="4900" type="Mechanism">Glucocorticoid Induced TNF Receptor (GITR) Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-02033" type="ciTarget"><TargetEntity id="88949446571333" type="siTarget">Tumor necrosis factor receptor superfamily member 1B</TargetEntity><TargetEntity id="764" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Ankylosing spondylitis - Sweden - Feb-2017</FirstLaunched><FirstLaunched>Psoriasis - Sweden - Feb-2017</FirstLaunched><FirstLaunched>Psoriatic arthritis - Sweden - Feb-2017</FirstLaunched><FirstLaunched>Rheumatoid arthritis - Sweden - Feb-2017</FirstLaunched><FirstLaunched>Spondylarthritis - Sweden - Feb-2017</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="1781">Psoriatic arthritis</Indication><Indication id="281">Psoriasis</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="2921">Spondylarthritis</Indication><Indication id="398">Ankylosing spondylitis</Indication></IndicationsPrimary><ActionsPrimary><Action id="8222">Type II TNF receptor modulator</Action><Action id="380">TNF agonist</Action><Action id="721">TNF binding agent</Action><Action id="511">TNF antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="396">Immunosuppressant</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="962">Biosimilar product</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="746">Solution</Technology><Technology id="84">Protein fusion</Technology><Technology id="894">Liquid formulation</Technology><Technology id="898">Formulation powder</Technology></Technologies><EphmraCodes><Ephmra><Code>L4</Code><Name>IMMUNOSUPPRESSIVE AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-05-22T20:26:49.000Z</LastModificationDate><ChangeDateLast>2019-05-23T00:00:00.000Z</ChangeDateLast><AddedDate>2017-08-30T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18767" linkType="Company"&gt;Pfizer&lt;/ulink&gt; has developed and launched Lifmior, a biosimilar version of &lt;ulink linkID="4567" linkType="Drug"&gt;etanercept&lt;/ulink&gt;,  a fusion protein comprising the extracellular domain of human p75 TNF receptor linked to the Fc portion of human IgG1, available for sc use [&lt;ulink linkID="1886789" linkType="Reference"&gt;1886789&lt;/ulink&gt;], [&lt;ulink linkID="1908228" linkType="Reference"&gt;1908228&lt;/ulink&gt;]. In the EU, it is indicated as monotherapy or in combination with methotrexate (MTX) for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adults when the response to disease-modifying anti-rheumatic drugs (DMARDs) has been inadequate; for the treatment of severe, active and progressive RA in adults not previously treated with MTX; for the treatment of polyarthritis and extended oligoarthritis in children and adolescents aged 2 years and above who have had an inadequate response to MTX; the treatment of psoriatic arthritis (PsA) in adolescents aged 12 years and above who have had an inadequate response to MTX; treatment of enthesitis-related arthritis in adolescents aged  12 years and above who have had an inadequate response to conventional therapy; for the treatment of active and progressive PsA in adults when the response to previous DMARDs has been inadequate; for the treatment of adults with severe active ankylosing spondylitis (AS) who have had an inadequate response to conventional therapy; for the treatment of adults with severe non-radiographic axial spondyloarthritis (SpA) who have had an inadequate response to nonsteroidal anti-inflammatory drugs; for the treatment of adults with moderate-to- severe plaque psoriasis who have had an inadequate response to other systemic therapy; and for the treatment of chronic severe plaque psoriasis in children and adolescents aged 6 years and above who are inadequately controlled by other systemic therapies [&lt;ulink linkID="1956218" linkType="Reference"&gt;1956218&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2017, the drug had been launched in Sweden [&lt;ulink linkID="2152255" linkType="Reference"&gt;2152255&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In December 2016, the EMA's CHMP recommended the drug for approval for RA, juvenile idiopathic arthritis, PsA, axial SpA, plaque psoriasis and pediatric plaque psoriasis [&lt;ulink linkID="1886789" linkType="Reference"&gt;1886789&lt;/ulink&gt;]; in February 2017,  approval was granted in the EU for  the treatment of RA, PsA,  AS, severe non-radiographic axial SpA, moderate-to-severe and chronic  plaque psoriasis  [&lt;ulink linkID="1908228" linkType="Reference"&gt;1908228&lt;/ulink&gt;], [&lt;ulink linkID="1956218" linkType="Reference"&gt;1956218&lt;/ulink&gt;]. By February 2017, the drug had been launched in Sweden [&lt;ulink linkID="2152255" linkType="Reference"&gt;2152255&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2921">Spondylarthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-02-28T00:00:00.000Z</StatusDate><Source id="2152255" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-02-28T00:00:00.000Z</StatusDate><Source id="2152255" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-02-28T00:00:00.000Z</StatusDate><Source id="2152255" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-02-28T00:00:00.000Z</StatusDate><Source id="2152255" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-02-28T00:00:00.000Z</StatusDate><Source id="2152255" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-02-13T00:00:00.000Z</StatusDate><Source id="1908228" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-02-13T00:00:00.000Z</StatusDate><Source id="1908228" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-02-13T00:00:00.000Z</StatusDate><Source id="1908228" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2921">Spondylarthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-02-13T00:00:00.000Z</StatusDate><Source id="1908228" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-02-13T00:00:00.000Z</StatusDate><Source id="1908228" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-16T00:00:00.000Z</StatusDate><Source id="1886789" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-16T00:00:00.000Z</StatusDate><Source id="1886789" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-16T00:00:00.000Z</StatusDate><Source id="1886789" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2921">Spondylarthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-16T00:00:00.000Z</StatusDate><Source id="1886789" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-16T00:00:00.000Z</StatusDate><Source id="1886789" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01874"><Name>TNF receptor</Name><SwissprotNumbers></SwissprotNumbers></Target><Target id="PTGT-02033"><Name>Type II TNF receptor</Name><SwissprotNumbers><Swissprot>P20333</Swissprot><Swissprot>P25119</Swissprot><Swissprot>Q80WY6</Swissprot></SwissprotNumbers></Target><Target id="PTGT-03212"><Name>Tumor necrosis factor ligand</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>